Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IM96 CAR-T Cells in Advanced Gastric/GEJ Adenocarcinoma
NCT07406984Phase 1Not yet recruiting
- Sponsor
- Immunochina Pharmaceuticals
- Start
- Mar 2026
- Primary completion
- May 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of IM96 in Adenocarcinoma of the stomach (GC) and adenocarcinoma of the gastroesophageal junction, sponsored by Immunochina Pharmaceuticals. Primary endpoint: Incidence of Treatment Related adverse events at 28 days. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
IM96
03
Conditions
Adenocarcinoma of the stomach (GC)adenocarcinoma of the gastroesophageal junction
Beyond the preview
Go deeper on NCT07406984.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07406984.